Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

CytoMed (NASDAQ: GDTC) stock is down 33% over the last 24 hours. GDTC stock fell in a mixture of real trading time, the aftermarket and now this morning. The reason for the decline is simply that it ...

CytoMed (NASDAQ: GDTC) stock is up 100%. The rise in GDTC stock seems to be coming from the award of a patent. This is a very silly idea, quite ridiculous. Of course, it's just great for those who ...

CytoMed Therapeutics is developing next-generation CAR-T cell therapies from γδ T cells for multiple solid tumor indications. The use of γδ T cells allows CytoMed to generate allogeneic, off-the-shelf ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

GDTC is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of GDTC shares has decreased $0.02 since the market last closed. This is a 1.85% ...

CytoMed Therapeutics Limited (GDTC) stock price is 1.06 and CytoMed Therapeutics Limited (GDTC) 10-day simple moving average is 1.05. CytoMed Therapeutics Limited (GDTC) stock price is 1.06 and ...